Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent drug formulations, with its pipeline centered on opioid medications designed to resist misuse. The company filed a Form 10-Q with the SEC on November 9, 2020, under accession number 0001213900-20-035884, reflecting its status as a reporting company during its path to the public markets via a SPAC transaction. Operating in the healthcare and specialty pharmaceuticals sector, Ensysce has pursued regulatory approval for its proprietary MPAR and TAAP drug-safety technologies. For complete filing history, deal terms, and ongoing status data on ENSC, sign up for full access at SpacDesk.